A T-lymphocyte white blood cell infected with AIDS virus
For more than a quarter-century, the medical community has been trying to develop a vaccine against AIDS--and for more than a quarter-century, it has been disappointed. Earlier this year, it seemed that science had its best shot yet, with a large trial of a new vaccine that would use a novel strategy to protect the body against HIV. In September, however, the results were announced, and this vaccine too had failed. Its developer, Merck, has now released an analysis of the trial, and while the vaccine performed as poorly as reported, the reasons it failed provide insight into what might make...
To continue reading:
or
Log-In
